Bausch + Lomb CEO Brent Saunders searches for smaller deals while 'digesting' $1.75B Xiidra move
In his second stint as CEO of Bausch + Lomb, Brent Saunders has stayed true to his dealmaking reputation.
Just a few months after taking the helm in March, Saunders announced a deal to acquire the dry eye drug Xiidra from Novartis for $1.75 billion. The $6.6 billion eye-care specialist will now need time to work through that transaction, which is expected to close by year’s end, while keeping an eye out for smaller deals, Saunders told Endpoints News in a Wednesday interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.